Form 4: Myriad Genetics CEO Paul J. Diaz Acquires Shares Following Performance-Based Vesting

Paul J. Diaz, President and CEO of Myriad Genetics, acquired 114,828 shares of common stock on February 7, 2025, following the vesting of performance-based restricted stock units (PSUs).

Summary

• On February 7, 2025, Paul J. Diaz, the President and CEO of Myriad Genetics, acquired 114,828 shares of common stock.
• This acquisition resulted from the vesting of performance-based restricted stock units (PSUs) that were initially granted on March 22, 2022.
• The Compensation and Human Capital Committee determined the final award amount based on the achievement of pre-determined performance metrics.
• Each PSU represents a contingent right to receive one share of Myriad Genetics' common stock and vests on March 22, 2025.
• Following the transaction, Diaz directly owns 1,077,206 shares of Myriad Genetics.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CEO acquiring shares due to performance-based vesting suggests confidence in the company's performance and alignment with shareholder interests.

Positives

• The vesting of performance-based restricted stock units suggests that the company achieved certain pre-determined performance metrics, which is a positive indicator.
• The CEO's increased stake in the company aligns his interests with those of the shareholders.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's confidence in the company's future prospects. The acquisition of shares by the CEO, particularly following the vesting of performance-based units, is generally viewed positively.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive sign, aligning management's interests with their own.
• Employees may see the vesting of performance-based units as an indicator of the company's success in achieving its goals.

Key Dates